Search and Filter
Results per Page:
Coordination of COVID-19 Vaccine Clinical Trials Produces a ‘Treasure Trove’ of Data and a Model for the Future
Harmonized approach and vast database of trial participants could bolster future research well beyond SARS-CoV-2
Phase 3 Mosaic-Based Investigational HIV Vaccine Study Discontinued Following Disappointing Results of Planned Data Review
HVTN researchers and ethicists say findings will help guide new approaches to HIV vaccine studies
Newly defined biomarker may accelerate clinical trials for vaccines to prevent HIV-1 infection
A study published in the Aug. 22, 2022 issue of Nature Medicine identifies a new biomarker that appears effective as a surrogate endpoint to reliably predict the ability of broadly neutralizing monoclonal antibodies to prevent acquisition of HIV-1, the most common type of the virus that causes AIDS.
HVTN at the 24th International AIDS Conference in Montreal
HVTN researchers and faith leaders will address HIV and SARS-CoV-2, neutralizing antibodies, future directions for research, lessons from COVID-19 community engagement, overcoming HIV stigma and discrimination, and more
CoVPN Trial: Novavax’s Traditional COVID-19 Vaccine Correlates to Strong Antibody Response, Protection Against SARS-CoV-2
Response comparable to mRNA vaccines and if authorized, could help bolster global vaccine supplies
Antibody Mediated Prevention (AMP) Trials Data Published by the New England Journal of Medicine
Most advanced clinical trials testing broadly neutralizing antibody against HIV demonstrate efficacy against sensitive strains